SEARCH

SEARCH BY CITATION

References

  • Akin, C., Brockow, K., D’Ambrosio, C., Kirshenbaum, A.S., Ma, Y., Longley, B.J. & Metcalfe, D.D. (2003) Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Experimental Hematology, 31, 686692.
  • Akin, C., Fumo, G., Yavuz, A.S., Lipsky, P.E., Neckers, L. & Metcalfe, D.D. (2004) A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood, 103, 32223225.
  • Bonkobara, M., Zukas, P.K., Shikano, S., Nakamura, S., Cruz, P.D. & Ariizumi, K. (2001) Epidermal Langerhans cell-targeted gene expression by a dectin-2 promoter. Journal of Immunology, 167, 68936900.
  • Büttner, C., Henz, B.M., Welker, P., Sepp, N.T. & Grabbe, J. (1998) Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. Journal of Investigative Dermatology, 111, 12271231.
  • Care, R.S., Valk, P.J., Goodeve, A.C., Abu-Duhier, F.M., Geertsma-Kleinekoort, W.M., Wilson, G.A., Gari, M.A., Peake, I.R., Löwenberg, B. & Reilly, J.T. (2003) Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. British Journal of Haematology, 121, 775777.
  • Dank, G., Chien, M.B. & London, C.A. (2002) Activating mutations in the catalytic or juxtamembrane domain of c-kit in splenic mast cell tumors of cats. American Journal of Veterinary Research, 63, 11291133.
  • Demetri, G.D., Von Mehren, M., Blanke, C.D., Van den Abbeele, A.D., Eisenberg, B., Roberts, P.J., Heinrich, M.C., Tuveson, D.A., Singer, S., Janicek, M., Fletcher, J.A., Silverman, S.G., Silberman, S.L., Capdeville, R., Kiese, B., Peng, B., Dimitrijevic, S., Druker, B.J., Corless, C., Fletcher, C.D. & Joensuu, H. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New England Journal of Medicine, 347, 472480.
  • Druker, B.J., Guilhot, F., O’Brien, S.G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M.W., Silver, R.T., Goldman, J.M., Stone, R.M., Cervantes, F., Hochhaus, A., Powell, B.L., Gabrilove, J.L., Rousselot, P., Reiffers, J., Cornelissen, J.J., Hughes, T., Agis, H., Fischer, T., Verhoef, G., Shepherd, J., Saglio, G., Gratwohl, A., Nielsen, J.L., Radich, J.P., Simonsson, B., Taylor, K., Baccarani, M., So, C., Letvak, L. & Larson, R.A. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine, 355, 24082417.
  • Frost, M.J., Ferrao, P.T., Hughes, T.P. & Ashman, L.K. (2002) Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Molecular Cancer Therapeutics, 1, 11151124.
  • Garcia-Montero, A.C., Jara-Acevedo, M., Teodosio, C., Sanchez, M.L., Nunez, R., Prados, A., Aldanondo, I., Sanchez, L., Dominguez, M., Botana, L.M., Sanchez-Jimenez, F., Sotlar, K., Almeida, J., Escribano, L. & Orfao, A. (2006) KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood, 108, 23662372.
  • Hartmann, K., Wardelmann, E., Ma, Y., Merkelbach-Bruse, S., Preussner, L.M., Woolery, C., Baldus, S.E., Heinicke, T., Thiele, J., Buettner, R. & Longley, B.J. (2005) Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology, 129, 10421046.
  • Heinrich, M.C., Corless, C.L., Demetri, G.D., Blanke, C.D., Von Mehren, M., Joensuu, H., McGreevey, L.S., Chen, C.J., Van den Abbeele, A.D., Druker, B.J., Kiese, B., Eisenberg, B., Roberts, P.J., Singer, S., Fletcher, C.D., Silberman, S., Dimitrijevic, S. & Fletcher, J.A. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. Journal of Clinical Oncology, 21, 43424349.
  • Heinrich, M.C., Joensuu, H., Demetri, G.D., Corless, C.L., Apperley, J., Fletcher, J.A., Soulieres, D., Dirnhofer, S., Harlow, A., Town, A., McKinley, A., Supple, S.G., Seymour, J., Di Scala, L., Van Oosterom, A., Herrmann, R., Nikolova, Z. & McArthur, A.G. (2008) Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clinical Cancer Research, 14, 27172725.
  • Hoffmann, K.M., Moser, A., Lohse, P., Winkler, A., Binder, B., Sovinz, P., Lackner, H., Schwinger, W., Benesch, M. & Urban, C. (2008) Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation. Blood, 112, 16551657.
  • Isotani, M., Tamura, K., Yagihara, H., Hikosaka, M., Ono, K., Washizu, T. & Bonkobara, M. (2006) Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate. Veterinary Immunology and Immunopathology, 114, 168172.
  • Isotani, M., Ishida, N., Tominaga, M., Tamura, K., Yagihara, H., Ochi, S., Kato, R., Kobayashi, T., Fujita, M., Fujino, Y., Setoguchi, A., Ono, K., Washizu, T. & Bonkobara, M. (2008) Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. Journal of Veterinary Internal Medicine, 22, 985988.
  • Lanternier, F., Cohen-Akenine, A., Palmerini, F., Feger, F., Yang, Y., Zermati, Y., Barète, S., Sans, B., Baude, C., Ghez, D., Suarez, F., Delarue, R., Casassus, P., Bodemer, C., Catteau, A., Soppelsa, F., Hanssens, K., Arock, M., Sobol, H., Fraitag, S., Canioni, D., Moussy, A., Launay, J.M., Dubreuil, P., Hermine, O. & Lortholary, O. (2008) Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. PLoS ONE, 3, e1906.
  • Letard, S., Yang, Y., Hanssens, K., Palmérini, F., Leventhal, P.S., Guéry, S., Moussy, A., Kinet, J.P., Hermine, O. & Dubreuil, P. (2008) Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Molecular Cancer Research, 6, 11371145.
  • Litster, A.L. & Sorenmo, K.U. (2006) Characterisation of the signalment, clinical and survival characteristics of 41 cats with mast cell neoplasia. Journal of Feline Medicine and Surgery, 8, 177183.
  • Longley, B.J., Metcalfe, D.D., Tharp, M., Wang, X., Tyrrell, L., Lu, S.Z., Heitjan, D. & Ma, Y. (1999) Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proceedings of the National Academy of Sciences of the United States of America, 96, 16091614.
  • Longley, B.J., Reguera, M.J. & Ma, Y. (2001) Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leukemia Research, 25, 571576.
  • Miller, M.A., Nelson, S.L., Turk, J.R., Pace, L.W., Brown, T.P., Shaw, D.P., Fischer, J.R. & Gosser, H.S. (1991) Cutaneous neoplasia in 340 cats. Veterinary Pathology, 28, 389395.
  • Orfao, A., Garcia-Montero, A.C., Sanchez, L. & Escribano, L. (2007) Recent advances in the understanding of mastocytosis: the role of KIT mutations. British Journal of Haematology, 138, 1230.
  • Pardanani, A., Elliott, M., Reeder, T., Li, C.Y., Baxter, E.J., Cross, N.C. & Tefferi, A. (2003) Imatinib for systemic mast-cell disease. Lancet, 362, 535536.
  • Roskoski, R. (2005) Structure and regulation of Kit protein-tyrosine kinase – the stem cell factor receptor. Biochemical and Biophysical Research Communications, 338, 13071315.
  • Spangler, W.L. & Culbertson, M.R. (1992) Prevalence and type of splenic diseases in cats: 455 cases (1985-1991). Journal of the American Veterinary Medical Association, 201, 773776.
  • Vega-Ruiz, A., Cortes, J.E., Sever, M., Manshouri, T., Quintás-Cardama, A., Luthra, R., Kantarjian, H.M. & Verstovsek, S. (2009) Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leukemia Research, 33, 14811484.
  • Vignetti, M., Fazi, P., Cimino, G., Martinelli, G., Di Raimondo, F., Ferrara, F., Meloni, G., Ambrosetti, A., Quarta, G., Pagano, L., Rege-Cambrin, G., Elia, L., Bertieri, R., Annino, L., Foà, R., Baccarani, M. & Mandelli, F. (2007) Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) LAL0201-B protocol. Blood, 109, 36763678.
  • Wilcock, B.P., Yager, J.A. & Zink, M.C. (1986) The morphology and behavior of feline cutaneous mastocytomas. Veterinary Pathology, 23, 320324.
  • Yarden, Y. & Ullrich, A. (1988) Growth factor receptor tyrosine kinases. Annual Review of Biochemistry, 57, 443478.
  • Yuzawa, S., Opatowsky, Y., Zhang, Z., Mandiyan, V., Lax, I. & Schlessinger, J. (2007) Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell, 130, 323334.
  • Zhang, L.Y., Smith, M.L., Schultheis, B., Fitzgibbon, J., Lister, T.A., Melo, J.V., Cross, N.C. & Cavenagh, J.D. (2006) A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leukemia Research, 30, 373378.